# Prehospital blood pressure lowering in acute hemorrhagic stroke: a systematic review and meta-analysis of randomized controlled clinical trials

## TL;DR

This study reviews clinical trials to assess if lowering blood pressure before hospital arrival helps patients with acute hemorrhagic stroke.

## Contribution

The study provides a meta-analysis of prehospital blood pressure-lowering in acute hemorrhagic stroke, comparing it to usual care.

## Key findings

- Prehospital BP-lowering showed no significant improvement in functional outcomes or survival.
- No significant differences were found in serious adverse events or hematoma expansion.
- Urapidil was found to be better than glyceryl trinitrate in reducing risks.

## Abstract

Elevated blood pressure (BP) in acute hemorrhagic stroke has been associated with adverse clinical outcomes. Limited data from randomized controlled clinical trials (RCTs) indicate that early BP management, in the prehospital setting, may be safe and beneficial. We sought to evaluate the efficacy and safety of prehospital BP-lowering in acute hemorrhagic stroke when compared to usual care.

We conducted a systematic review and meta-analysis including available RCTs evaluating prehospital BP-lowering among acute hemorrhagic stroke patients. The pooled risk ratio (RR) of a 3-month good functional outcome, defined as modified-Rankin-Scale scores of 0-2 and all-cause 3-month mortality were the primary efficacy and safety outcomes, respectively. Secondary outcomes included the pooled RR of hematoma expansion (HE) and serious adverse events (SAEs).

A total of four RCTs were included, comprising 642 patients treated with prehospital BP-lowering therapies and 617 patients receiving usual care. Prehospital BP-lowering was associated with similar rates of good functional outcome (RR: 1.07; 95% CI, 0.52–2.19) and all-cause mortality (RR: 0.90; 95% CI, 0.60–1.35) at 3 months, compared to usual care. The risk of SAEs (RR: 0.97; 95% CI, 0.74–1.26) and HE (RR: 1.05; 95% CI, 0.45–2.46) did not significantly differ between the two groups. Subgroup analyses revealed the superiority of the α-adrenoreceptor blocker urapidil compared to glyceryl trinitrate in terms of reducing SAE risk and HE.

Our meta-analysis indicates that prehospital BP-lowering in acute hemorrhagic stroke does not improve functional outcome and survival. Future RCTs conducted in mobile stroke units, and exclusively focusing on patients with acute hemorrhagic stroke, are required.

Graphical abstract